Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

Authors: Nobumichi Tanaka, Akihide Hirayama, Tatsuo Yoneda, Katsunori Yoshida, Keiji Shimada, Noboru Konishi, Kiyohide Fujimoto

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

To assess the trends of risk classification and primary therapy in Japanese patients who were diagnosed with prostate cancer between 2004-2006 and 2007-2009.

Methods

A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009 (latter period).

Results

The proportion of patients with a high or greater risk significantly decreased in the latter period compared to the prior period (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, and 40% in the latter period. On the other hand, the proportion of radiation therapy was 14% in the prior period, but 24% in the latter period. The proportion of radical prostatectomy was the same in the two periods (30%). The primary therapy was significantly different between the two periods (p < 0.001).

Conclusions

Higher risk patients significantly decreased in the latter period compared to the prior period. The use of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in Japan.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y: Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010, 40: 588-592. 10.1093/jjco/hyq008.CrossRefPubMed Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y: Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010, 40: 588-592. 10.1093/jjco/hyq008.CrossRefPubMed
2.
go back to reference Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: CaPSURE: time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003, 170: S21-S27. 10.1097/01.ju.0000095025.03331.c6.CrossRefPubMed Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: CaPSURE: time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003, 170: S21-S27. 10.1097/01.ju.0000095025.03331.c6.CrossRefPubMed
3.
go back to reference Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005, 12: 46-61.CrossRef Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol. 2005, 12: 46-61.CrossRef
4.
go back to reference Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H: Japan study group of prostate cancer (J-CaP): current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007, 37: 775-781. 10.1093/jjco/hym098.CrossRefPubMed Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H: Japan study group of prostate cancer (J-CaP): current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007, 37: 775-781. 10.1093/jjco/hym098.CrossRefPubMed
5.
go back to reference D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-974. 10.1001/jama.280.11.969.CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280: 969-974. 10.1001/jama.280.11.969.CrossRefPubMed
6.
go back to reference Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y: Oncological outcomes of the prostate cancer patients registered in 2004: report from the cancer registration committee of the JUA. Int J Urol. 2011, 18: 876-881. 10.1111/j.1442-2042.2011.02895.x.CrossRefPubMed Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y: Oncological outcomes of the prostate cancer patients registered in 2004: report from the cancer registration committee of the JUA. Int J Urol. 2011, 18: 876-881. 10.1111/j.1442-2042.2011.02895.x.CrossRefPubMed
7.
go back to reference Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: data from CaPSURE. J Urol. 2003, 170: 905-908. 10.1097/01.ju.0000081200.63275.0b.CrossRefPubMed Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: data from CaPSURE. J Urol. 2003, 170: 905-908. 10.1097/01.ju.0000081200.63275.0b.CrossRefPubMed
8.
go back to reference Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007, 178: S14-S19. 10.1016/j.juro.2007.03.135.CrossRefPubMedPubMedCentral Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007, 178: S14-S19. 10.1016/j.juro.2007.03.135.CrossRefPubMedPubMedCentral
9.
go back to reference Epstein JI, Allsbrook WC, Amin MB, Egevad LL, Grading ISUP: Committee: the international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005, 2005 (29): 1228-1242.CrossRef Epstein JI, Allsbrook WC, Amin MB, Egevad LL, Grading ISUP: Committee: the international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005, 2005 (29): 1228-1242.CrossRef
10.
go back to reference Cooperberg MR, Cowan J, Broering JM, Carroll PR: High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008, 26: 211-218. 10.1007/s00345-008-0250-7.CrossRefPubMedPubMedCentral Cooperberg MR, Cowan J, Broering JM, Carroll PR: High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008, 26: 211-218. 10.1007/s00345-008-0250-7.CrossRefPubMedPubMedCentral
11.
go back to reference Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H: Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009, 27: 4306-4313. 10.1200/JCO.2008.21.5228.CrossRefPubMedPubMedCentral Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H: Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009, 27: 4306-4313. 10.1200/JCO.2008.21.5228.CrossRefPubMedPubMedCentral
12.
go back to reference Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association: Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol. 2008, 15: 763-768. 10.1111/j.1442-2042.2008.02125.x.CrossRefPubMed Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association: Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol. 2008, 15: 763-768. 10.1111/j.1442-2042.2008.02125.x.CrossRefPubMed
13.
go back to reference Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA. 2003, 289: 1414-1420. 10.1001/jama.289.11.1414.CrossRefPubMed Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA. 2003, 289: 1414-1420. 10.1001/jama.289.11.1414.CrossRefPubMed
14.
go back to reference Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, Haramoto M, Hayashi Y, Nakagawa Y, Otani T, Watanabe S, Hirao Y: The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara uro-oncological research group registration. BMC Urol. 2011, 11: 6-10.1186/1471-2490-11-6.CrossRefPubMedPubMedCentral Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, Haramoto M, Hayashi Y, Nakagawa Y, Otani T, Watanabe S, Hirao Y: The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara uro-oncological research group registration. BMC Urol. 2011, 11: 6-10.1186/1471-2490-11-6.CrossRefPubMedPubMedCentral
15.
go back to reference Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease?. Int J Radiat Oncol Biol Phys. 2011, 79: 1310-1317. 10.1016/j.ijrobp.2010.01.006.CrossRefPubMed Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease?. Int J Radiat Oncol Biol Phys. 2011, 79: 1310-1317. 10.1016/j.ijrobp.2010.01.006.CrossRefPubMed
16.
go back to reference Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG: Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol. 2011, 185: 495-500. 10.1016/j.juro.2010.09.099.CrossRefPubMed Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG: Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol. 2011, 185: 495-500. 10.1016/j.juro.2010.09.099.CrossRefPubMed
Metadata
Title
Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009
Authors
Nobumichi Tanaka
Akihide Hirayama
Tatsuo Yoneda
Katsunori Yoshida
Keiji Shimada
Noboru Konishi
Kiyohide Fujimoto
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-588

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine